Abstract
The chiral monoaza-15-crown-5 lariat ethers annellated to methyl-4,6-O-benzylidene-α-D-glucopyranoside- (1) or – mannopyranoside (2) used as phase transfer catalysts in the Michael addition of 2-nitropropane to substituted chalcones and chalcone analogues resulted in a significant asymmetric induction. The type of substituent on the chalcone molecule was found to have a significant influence on both the chemical yield and the enantioselectivity of the reaction: 24 novel chiral Michael adducts were prepared in 14-68% ee. These ee values were somewhat lower than that experienced in the case of the unsubstituted chalcone (85% ee). In the series of chalcone analogues, the 1-naphthyl Michael adduct was formed in 87% ee. Using glucose-based crown ether 1, formation of the (+)-enantiomers was preferred, while applying mannose-based 2 as the catalyst, the (-)-enantiomers were in excess.
Keywords: Chiral crown ether, phase transfer catalysis, asymmetric Michael addition
Letters in Organic Chemistry
Title: Enantioselective Michael Addition of 2-Nitropropane to Substituted Chalcones and Chalcone Analogues Catalyzed by Chiral Crown Ethers Incorporating an α-D-Glucose or an α-D-Mannose Unit
Volume: 7 Issue: 6
Author(s): Attila Mako, Zsolt Rapi, Laszlo Drahos, Aron Szollosy, Gyorgy Keglevich and Peter Bako
Affiliation:
Keywords: Chiral crown ether, phase transfer catalysis, asymmetric Michael addition
Abstract: The chiral monoaza-15-crown-5 lariat ethers annellated to methyl-4,6-O-benzylidene-α-D-glucopyranoside- (1) or – mannopyranoside (2) used as phase transfer catalysts in the Michael addition of 2-nitropropane to substituted chalcones and chalcone analogues resulted in a significant asymmetric induction. The type of substituent on the chalcone molecule was found to have a significant influence on both the chemical yield and the enantioselectivity of the reaction: 24 novel chiral Michael adducts were prepared in 14-68% ee. These ee values were somewhat lower than that experienced in the case of the unsubstituted chalcone (85% ee). In the series of chalcone analogues, the 1-naphthyl Michael adduct was formed in 87% ee. Using glucose-based crown ether 1, formation of the (+)-enantiomers was preferred, while applying mannose-based 2 as the catalyst, the (-)-enantiomers were in excess.
Export Options
About this article
Cite this article as:
Mako Attila, Rapi Zsolt, Drahos Laszlo, Szollosy Aron, Keglevich Gyorgy and Bako Peter, Enantioselective Michael Addition of 2-Nitropropane to Substituted Chalcones and Chalcone Analogues Catalyzed by Chiral Crown Ethers Incorporating an α-D-Glucose or an α-D-Mannose Unit, Letters in Organic Chemistry 2010; 7 (6) . https://dx.doi.org/10.2174/157017810791824865
DOI https://dx.doi.org/10.2174/157017810791824865 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monitoring Inflammation, Humoral and Cell-mediated Immunity in Pancreas and Islet Transplants
Current Diabetes Reviews Reflections on MicroRNAs in Chronic Pulmonary Disease: Looking into the miR-ror and Crystal Ball
Inflammation & Allergy - Drug Targets (Discontinued) Regenerative Medicine Approaches in COVID-19 Pneumonia
Current Stem Cell Research & Therapy The Central Role of Leukotriene B4 in Epstein Barr Virus Activated Innate Immunity In Vitro
Current Immunology Reviews (Discontinued) Enhancement of TLR-Mediated Innate Immune Responses by Peptidoglycans through NOD Signaling
Current Pharmaceutical Design Sub-Chronic Exposure of Non-Observable Adverse Effect Dose of Terbufos Sulfone: Neuroinflammation in Diabetic and Non-Diabetic Rats
CNS & Neurological Disorders - Drug Targets The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Regulation of Blood Flow by Prostaglandins
Current Vascular Pharmacology Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Nenatal Drug Induced Nephrotoxicity : Old and Next Generation Biomarkers for Early Detection and Management of Neonatal Drug-Induced Nephrotoxicity, with Special Emphasis on uNGAL and on Metabolomics
Current Medicinal Chemistry Functional Immunoregulation by Heme Oxygenase 1 in Juvenile Autoimmune Diseases
Current Gene Therapy Ubiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Differential Gene Expression of <i>ASUN, NEMF, PTPRC</i> and <i>DHX29</i>: Candidate Biomarkers for the Diagnosis of Active and Latent Tuberculosis
Infectious Disorders - Drug Targets Calcineurin Inhibition and Development: Insights from Research Models
Current Enzyme Inhibition Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews Viral-Mediated Gene Transfer for Cancer Treatment
Current Pharmaceutical Biotechnology Novel Carriers for Controlled Site Specific Delivery of Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition